Immutep Limited

NasdaqGM:IMMP Stock Report

Market Cap: US$410.7m

Immutep Management

Management criteria checks 3/4

Immutep's CEO is Marc Voigt, appointed in Nov 2012, has a tenure of 13.25 years. total yearly compensation is A$1.17M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth $4.15M. The average tenure of the management team and the board of directors is 8.1 years and 3.8 years respectively.

Key information

Marc Voigt

Chief executive officer

AU$1.2m

Total compensation

CEO salary percentage46.51%
CEO tenure13.3yrs
CEO ownership1.0%
Management average tenure8.1yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Immutep Limited: Surging On Positive Head And Neck Data

May 08

Immutep Limited: Continuing To Make The Case For Eftilagimod

Jan 28

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 15

Immutep: Realizing The Expected Catalysts, With More To Come

May 01

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Oct 04

Immutep secures €1.8M cash in French government's research tax credit

Sep 23

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Aug 30

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Jul 06

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Jun 12

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Mar 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Jun 21

CEO Compensation Analysis

How has Marc Voigt's remuneration changed compared to Immutep's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025AU$1mAU$546k

-AU$61m

Mar 31 2025n/an/a

-AU$53m

Dec 31 2024n/an/a

-AU$44m

Sep 30 2024n/an/a

-AU$43m

Jun 30 2024AU$1mAU$477k

-AU$43m

Mar 31 2024n/an/a

-AU$42m

Dec 31 2023n/an/a

-AU$41m

Sep 30 2023n/an/a

-AU$40m

Jun 30 2023AU$1mAU$440k

-AU$40m

Mar 31 2023n/an/a

-AU$38m

Dec 31 2022n/an/a

-AU$37m

Sep 30 2022n/an/a

-AU$34m

Jun 30 2022AU$943kAU$428k

-AU$32m

Mar 31 2022n/an/a

-AU$29m

Dec 31 2021n/an/a

-AU$26m

Sep 30 2021n/an/a

-AU$28m

Jun 30 2021AU$995kAU$409k

-AU$30m

Mar 31 2021n/an/a

-AU$29m

Dec 31 2020n/an/a

-AU$27m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$926kAU$411k

-AU$13m

Mar 31 2020n/an/a

-AU$15m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$17m

Jun 30 2019AU$837kAU$399k

-AU$18m

Compensation vs Market: Marc's total compensation ($USD828.56K) is below average for companies of similar size in the US market ($USD2.27M).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.

CEO

Marc Voigt (52 yo)

13.3yrs
Tenure
AU$1,174,480
Compensation

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

Leadership Team

NamePositionTenureCompensationOwnership
Marc Voigt
CEO, MD13.3yrsAU$1.17m1.01%
$ 4.1m
Deanne Miller
COO, General Counsel & Joint Company Secretary13.3yrsAU$680.39k0.21%
$ 854.7k
Frederic Triebel
Chief Scientific Officer & Executive Director11.2yrsAU$945.88k0.78%
$ 3.2m
Christian Mueller
Chief Development Officer2.3yrsAU$505.98k0.26%
$ 1.1m
Stephan Winckels
Chief Medical Officerless than a yearno datano data
Indira Naidu
Joint Company Secretary5.1yrsno datano data
8.1yrs
Average Tenure
52yo
Average Age

Experienced Management: IMMP's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc Voigt
CEO, MD11.6yrsAU$1.17m1.01%
$ 4.1m
Frederic Triebel
Chief Scientific Officer & Executive Director3.4yrsAU$945.88k0.78%
$ 3.2m
Russell Howard
Independent Non-Executive Chairman12.8yrsAU$352.00k0.12%
$ 478.7k
Pete Meyers
Independent Non-Executive Deputy Chairman12yrsAU$76.48k0.27%
$ 1.1m
Martine Piccart
Chairman of Clinical Advisory Board8.7yrsno datano data
Scott Antonia
Member of Clinical Advisory Board3.8yrsno datano data
Leisha Emens
Member of Clinical Advisory Board3.8yrsno datano data
Elisabeth Boyce
Independent Non-Executive Director2.8yrsAU$100.85k0.029%
$ 117.9k
Salah-Eddin Al-Batran
Member of Clinical Advisory Board8.7yrsno datano data
Martin Forster
Member of Clinical Advisory Board3.8yrsno datano data
Hans Wildiers
Member of Clinical Advisory Board3.8yrsno datano data
3.8yrs
Average Tenure
62.5yo
Average Age

Experienced Board: IMMP's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/19 10:24
End of Day Share Price 2026/02/19 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immutep Limited is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
Melissa BensonBarrenjoey Markets Pty Limited